SCHEMBL5553620

SCHEMBL5553620

C=CC(=O)Nc1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 10/20 0.50
▸ GAA P10253 1/20 0.41
▸ F13A1 P00488 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TGM1 P22735 1/20 0.41
▸ TGM3 Q08188 1/20 0.41
▸ TSHR P16473 4/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ NPC1 O15118 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4732340 0.74 ALDH1A1 (0.62) TGM2F13A1LMNATGM1TGM3
SCHEMBL20379487 0.71 TGM2 (0.50) TGM2F13A1LMNATGM1TGM3
SCHEMBL25294152 0.71 TGM2 (0.46) TGM2F13A1LMNATGM1TGM3
SCHEMBL18010044 0.71 TGM2 (0.41) TGM2F13A1LMNATGM1TGM3
SCHEMBL21810569 0.71 GAA (0.55) GAALMNATSHRMAPK1NPC1
SCHEMBL30368203 0.70 TGM2 (0.41) TGM2F13A1LMNATGM1TGM3
SCHEMBL25247241 0.70 TGM2 (0.41) TGM2F13A1LMNATGM1TGM3
SCHEMBL28328517 0.70 TGM2 (0.58) TGM2F13A1LMNATGM1TGM3
SCHEMBL31043510 0.70 TGM2 (0.42) TGM2F13A1LMNATGM1TGM3
SCHEMBL26026744 0.70 TGM2 (0.48) TGM2F13A1LMNATGM1TGM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773310-A2 ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-04-18 — — EP claimed
WO-2006025924-A2 ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-03-09 — — WO claimed
US-20250032398-A1 HIGH MOLECULAR WEIGHT BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES AND HYDROPHILIC MONOMERS, COMPOSITIONS, AND APPLICATIONS THEREOF ISP INVESTMENTS LLC (US) 2025-01-30 — — US disclosed
US-10676554-B2 Polymer compound, film obtained by hardening this polymer compound and electronic device comprising this film SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-06-09 — — US disclosed
US-20190382519-A1 CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF ISP INVESTMENTS LLC (US) 2019-12-19 — — US disclosed
US-20190211123-A1 POLYMER COMPOUND, FILM OBTAINED BY HARDENING THIS POLYMER COMPOUND AND ELECTRONIC DEVICE COMPRISING THIS FILM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-07-11 — — US disclosed
WO-2018132548-A1 CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF ISP INVESTMENTS LLC (US) 2018-07-19 — — WO disclosed
EP-1773310-A2 ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-04-18 — — EP disclosed
WO-2006025924-A2 ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190382519-A1 CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF ADSL, ABHD6, APH1B TGM2 1972/4885GAA 711/4885F13A1 1204/4885
US-20250032398-A1 HIGH MOLECULAR WEIGHT BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES AND HYDROPHILIC MONOMERS, COMPOSITIONS, AND APPLICATIONS THEREOF PCNA, ADSL, APH1B TGM2 2386/4885GAA 812/4885F13A1 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback